Send the following on WhatsApp
Continue to Chat基石藥業宣佈擇捷美(R)(舒格利單抗注射液)一線治療食管鱗癌的註冊性臨床研究達到主要終點,擬遞交新適應症上市申請 https://geneonline.news/%e5%9f%ba%e7%9f%b3%e8%97%a5%e6%a5%ad%e5%ae%a3%e4%bd%88%e6%93%87%e6%8d%b7%e7%be%8er%ef%bc%88%e8%88%92%e6%a0%bc%e5%88%a9%e5%96%ae%e6%8a%97%e6%b3%a8%e5%b0%84%e6%b6%b2%ef%bc%89%e4%b8%80%e7%b7%9a/